Update on access to Dupilumab for eligible NHS England patients with chronic rhinosinusitis with nasal polyps (CRSwNP)
NICE, the National Institute for Health and Care Excellence, mandated that Dupilumab be made available to eligible* NHS eligible patients with severe CRSwNP within 90 days of it being approved. That 90 days has now passed. The drug is being funded centrally by NHS England. This means that all hospitals across England should now be able to prescribe the drug to eligible patients. To look at this a different way, all eligible NHS patients in England should have access to the drug.
We would encourage anyone with severe CRSwNP who believes that they are eligible for Dupilumab to speak with their ENT Consultant about how they can be prescribed it.
Everyone who is eligible for NICE-approved treatments should be able to access them, regardless of where they live. We would really like to hear from any eligible patients who are told that they are unable to be given the drug, and the reasons why. Please contact us at info@smelltaste.org.uk.
*Dupilumab, as an add-on to intranasal corticosteroids, can be used as an option to treat severe chronic rhinosinusitis with nasal polyps in adults if:
• the condition is not controlled well enough by systemic corticosteroids or sinus surgery, and
• they have had at least 1 sinus surgery, and
• the 22-item sinonasal outcomes test (SNOT-22) score is at least 50.
